Advertisement

Journal of Neuro-Oncology

, Volume 10, Issue 2, pp 165–171 | Cite as

Brain lesions following combined treatment with methotrexate and craniospinal irradiation

  • Cruz-Sanchez F. F. 
  • J. Artigas
  • J. Cervos-Navarro
  • M. L. Rossi
  • R. Ferszt
Clinical Study

Summary

Eight patients with meningeal seeding by carcinoma or lymphomas were treated with intravenous (i.v.) and/or intrathecal (i.th.) Methotrexate (MTX). Seven patients received additional craniospinal irradiation and in all seven a fatal encephalopathy developed.

On the bases of clinical and morphological findings we identified an acute and a delayed form of encephalopathy and concluded that the concurrent administration of Methotrexate and of craniospinal irradiation increases considerably the risk of brain damage.

Key words

leucoencephalopaty Methotrexate central nervous system craniospinal irradiation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bleyer WA: Neurologic sequelae of Methotrexate and ionizing radiation: a new classification. Cancer Treatment Report (suppl) 65: 89–98, 1981Google Scholar
  2. 2.
    Melhorn DK, Fisher BJ, Newmann AJ: Studies on the use of ‘prophylactic’ intratechal methopterin in childhood leukemia. Blood 36: 55–60, 1970Google Scholar
  3. 3.
    Pinkel D, Simone J, Hustu HO, Aur RJA: Nine years experience with ‘total therapy’ of childhood acute lymphocytic leukemia. Pediatrics 50: 246–251, 1972Google Scholar
  4. 4.
    Yap HJ, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenshein GR: Treatment for meningeal carcinomatosis in breast cancer. Cancer 49: 219–222, 1982Google Scholar
  5. 5.
    Ongerboer de Visser BW, Somers R, Nooyen WH, Heerde P van, Hart AM, Mcvie GJ: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: 1565–1572, 1983Google Scholar
  6. 6.
    Dejerassi I, Kim JS, Regger A: Response of astrocytoma to high dose methotrexate with citrovorum factor rescue. Cancer 55: 2741–2747, 1985Google Scholar
  7. 7.
    Craft AW, Kay HEM, Lawson DN, Mcelawain TJ: Methotrexate induced malabsorption in children with acute lymphoblastic leukemia. Br Med J 2: 1511–1512, 1977Google Scholar
  8. 8.
    Scully RE, Mark EJ, Mcneely BV: Methotrexate pneumonitis. NEJ Med 312: 359–367, 1985Google Scholar
  9. 9.
    Hendin B, DeVivo DC, Torack R, Lell ME, Ragab AH, Vietti TJ: Parenchymatous degeneration of the central nervous system in childhood leukemia. Cancer 33: 468–482, 1974Google Scholar
  10. 10.
    Price R, Jamieson P: The central nervous system in childhood leukaemia: II Subacute leukoencephalopathy. Cancer 35: 306–318, 1975Google Scholar
  11. 11.
    Rubinstein LJ, Hermann MM, Long TF, Wilbur JR: Disseminated necrotizing leukoencephalopathy, a complication of treated central nervous system leukemia and lymphoma. Cancer 35: 291–305, 1975Google Scholar
  12. 12.
    Evans AE, Craig M: Central nervous system involvement in children with acute leukemia. A study of 921 patients. Cancer 17: 256–258, 1964Google Scholar
  13. 13.
    Wahidhal I, Markum AH, Abdulasalam M, Muslichan S, Odang A: Prophylactic treatment of meningeal leukemia in children by intrathecal Methotrexate. Acta Haemat 47: 81–88,1972Google Scholar
  14. 14.
    Wasserstron WR, Glass J, Posner JB: Diagnosis and treatment of leptomeningeal metastasis from solid tumours. Cancer 49: 759–772, 1982Google Scholar
  15. 15.
    DeVivo DC, Malas D, Nelson JS, Land VJ: Leukoencephalopathy in childhood leukemia. Neurology 27: 609–613, 1977Google Scholar
  16. 16.
    Liu MH, Maurers HS, Vongsvivut S, Longway JJ: Methotrexate encephalopathy. Hum Path 9: 635–648, 1978Google Scholar
  17. 17.
    Ebels EJ: Iatrogenic damage to the central nervous system in malignant systemic disease. Acta Neuropathol (suppl) VII: 352–355, 1981Google Scholar
  18. 18.
    Touboul E, Fauchon F, Merle-Beral H: Neurotoxicitee de l'administration de Methotrexate intrarachidien et de l'irradiation externe meningo-encephalique au cours des meningites carcinomateuses. Nouv Rev Fr Hematol 23: 299–301, 1981Google Scholar
  19. 19.
    Geisser CF, Bishop V, Jaffe N, Furman L, Traggis D, Frei IE: Adverse effects of intratechal Methotrexate in children with acute leukemia in remission. Blood 45: 189–195, 1975Google Scholar
  20. 20.
    Gagliano R, Constanzi J: Paraplegia following intratechal Methotrexate: a report of a case and review of the literature. Cancer 37: 1663–1668, 1976Google Scholar
  21. 21.
    Smith B: Brain damage after intratechal Methotrexate. J Neurol Neurosurg Psychiat 38: 810–815, 1975Google Scholar
  22. 22.
    Livrea P, Trojamo M, Simone IL, Zimatore GB, Logroscino GC, Pisicchio L, Lojocono G, Colella R, Ceci A: Acute changes in blood-CSF barrier permeability to serum proteins after intratechal Methotrexate and CNS irradiation. J Neurol 232: 336–339, 1985Google Scholar
  23. 23.
    Mizutani T, Morimatsu Y, Hayakawa K: Necrotizing leukoencephalopathy and treated multiple myeloma. Acta Pathol Japan 34: 655–662, 1984Google Scholar
  24. 24.
    Rubin R, Owens E, Rall D: Transport of Methotrexate by the choroid plexus. Cancer Res 28: 689–694, 1968Google Scholar
  25. 25.
    Gregory TF, Renneles ML, Blaumanis OR, Fujimoto K: A method for microscopic studies of cerebral angioarchitecture and vascular-parenchymal relationship, based on the demonstration of ‘paravascular’ fluid pathway in the mammalian central nervous system. J Neurosci Meth 14: 5–14, 1985Google Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Cruz-Sanchez F. F. 
    • 1
  • J. Artigas
    • 2
  • J. Cervos-Navarro
    • 2
  • M. L. Rossi
    • 3
  • R. Ferszt
    • 2
  1. 1.Neurological Tissue Bank, Hospital Clinico I ProvincialUniversity of BarcelonaSpain
  2. 2.Institute of NeuropathologyFree University of BerlinGermany
  3. 3.Dept. of NeuropathologyMidland Centre for Neurology & Neurosurgery, Holly Lane, SmethwickWarley, BirminghamUK

Personalised recommendations